ReGARDD: Regulatory strategies during COVID-19

RTI will be hosting a webinar as part of the CTSA-supported ReGARDD regulatory forum on the impact of COVID-19 on regulatory pathways and clinical studies. There will be four speakers who will discuss regulatory strategies to navigate processes during the COVID-19 pandemic and the challenges of running clinical trials.

Presentations:

• Implications of COVID-19 on drug regulatory approvals and inspection processes - Michael Hinkle, JD, K&L Gates (9:00-9:30 AM)
• The Impact of COVID-19 on the FDA - David Rothkopf, MSME, MBA, President of MEDicept Inc (9:30-10:00 AM)
• Bioethics and human trials during the COVID-19 epidemic - Derry Ridgeway, MD, JD (10:00-10:30 AM)
• The NHLBI-CONNECTS program and the challenges of running COVID clinical studies - Antonello Punturieri, MD, PhD Scientific Program Director, NHLBI (10:30-11:00 AM)

If you have any questions, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Register